GlaxoSmithKline mulls more spinoffs amid a widespread rethink

Months after announcing plans to pursue an IPO for its HIV-focused joint venture, GlaxoSmithKline ($GSK) says it may take a similar tack with some of its other businesses. In an interview with Reuters, GSK chief Andrew Witty said his company is open to breaking up some of its operation if it'll create more shareholder value, modeling its moves on the planned IPO for ViiV Healthcare. GSK is also rolling out a company-wide reorganization, looking to carve £1 billion ($1.6 billion) out of its annual budget, cutting more than 900 jobs and curtailing its R&D budget. News

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.